NSE - Delayed Quote • INR
Biocon Limited (BIOCON.NS)
At close: 3:29 PM GMT+5:30
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. | Founder & Executive Chairperson | 30M | -- | 1953 |
| Mr. Siddharth Mittal BCom, CA, CPA | MD, CEO & Director | 47.88M | -- | 1978 |
| Mr. Peter James Jonathan Bains | Group Chief Executive Officer | 3.28M | -- | 1957 |
| Mr. Arun Gupta | Head of Operations | -- | -- | -- |
| Mr. Atanu Roy | Group Chief Information Officer | -- | -- | -- |
| Mr. Saurabh Paliwal | Head of Investor Relations | -- | -- | -- |
| Mr. Mayank Verma | Company Secretary & Compliance Officer | 5.75M | -- | -- |
| Ms. Seema Shah Ahuja BA, MBA | Global Head of Communications & Corporate Brand | -- | -- | 1966 |
| Ms. Maninder Kapoor Puri | Head of Human Resources | -- | -- | 1973 |
| Mr. Paul Vazhayil Thomas | Chief Commercial Officer, U.S. & Portfolio Strategy & Business Dev, Adv mkts of Biosimilars Business | -- | -- | 1973 |
Biocon Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16,545
Description
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.
Corporate Governance
Biocon Limited’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 1; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Jul 07, 2023Ex-Dividend Date
Upcoming Events
May 16, 2024
Biocon Limited Earnings Call
Related Tickers
SYNGENE.NS Syngene International Limited
698.60
-0.07%
LYKALABS.NS Lyka Labs Limited
123.15
-2.26%
DCAL.NS Dishman Carbogen Amcis Limited
229.65
-1.61%
SUPRIYA.NS Supriya Lifescience Limited
409.50
-1.04%
TAKE.NS TAKE Solutions Limited
23.45
-0.42%
ALBPS.PA Biophytis S.A.
0.0023
+4.55%
BLUEJET.NS Blue Jet Healthcare Limited
384.60
-1.83%
CONCORDBIO.NS Concord Biotech Limited
1,660.05
+1.45%
NONOF Novo Nordisk A/S
124.64
+0.92%
GPCR Structure Therapeutics Inc.
38.94
-0.10%